---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110789"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:36:06.342009+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027

## Summary
- Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.
- Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.
- Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.
- G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.
- No revenue reported; clinical-stage immunology company with no approved products.

## SEC filing metadata
- accession: 0001104659-25-110789
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/0001104659-25-110789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/tm2531128d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110789
- JSON: https://secwatch.observer/filing/0001104659-25-110789.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.